Technical Analysis for 0R1B - Biogen Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| New Uptrend | Bullish | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Crossed Above 20 DMA | Bullish | 3.36% | |
| Multiple of Ten Bullish | Other | 3.36% | |
| Inside Day | Range Contraction | 3.36% | |
| Gapped Up | Strength | 3.36% | |
| 20 DMA Resistance | Bearish | 4.50% |
| Alert | Time |
|---|---|
| 20 DMA Support | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
| Up 1% | 1 day ago |
| Down 1% | 1 day ago |
| Possible Inside Day | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Keywords: Medical Specialties Drugs Monoclonal Antibodies Alzheimer's Disease Multiple Sclerosis Organ Systems Immunosuppressants Plaque Psoriasis
Classification
Keywords: Medical Specialties Drugs Monoclonal Antibodies Alzheimer's Disease Multiple Sclerosis Organ Systems Immunosuppressants Plaque Psoriasis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 319.76 |
| 52 Week Low | 189.585 |
| Average Volume | 2,687 |
| 200-Day Moving Average | 243.63 |
| 50-Day Moving Average | 213.07 |
| 20-Day Moving Average | 201.67 |
| 10-Day Moving Average | 197.22 |
| Average True Range | 5.10 |
| RSI (14) | 55.16 |
| ADX | 33.15 |
| +DI | 28.48 |
| -DI | 22.57 |
| Chandelier Exit (Long, 3 ATRs) | 202.36 |
| Chandelier Exit (Short, 3 ATRs) | 204.89 |
| Upper Bollinger Bands | 214.53 |
| Lower Bollinger Band | 188.80 |
| Percent B (%b) | 0.8 |
| BandWidth | 12.75 |
| MACD Line | -4.36 |
| MACD Signal Line | -6.01 |
| MACD Histogram | 1.6467 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 224.49 | ||||
| Resistance 3 (R3) | 222.80 | 216.06 | 221.96 | ||
| Resistance 2 (R2) | 216.06 | 212.19 | 216.90 | 221.12 | |
| Resistance 1 (R1) | 212.68 | 209.80 | 214.37 | 214.37 | 220.27 |
| Pivot Point | 205.94 | 205.94 | 206.78 | 206.78 | 205.94 |
| Support 1 (S1) | 202.56 | 202.07 | 204.25 | 204.25 | 198.35 |
| Support 2 (S2) | 195.82 | 199.68 | 196.66 | 197.50 | |
| Support 3 (S3) | 192.44 | 195.82 | 196.66 | ||
| Support 4 (S4) | 194.13 |
